soul trial oral semaglutide cardiovascular outcomes results 2024 2025 Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π soul trial oral semaglutide cardiovascular
Description
EVOKE and EVOKE+ are two trials evaluating oral once-daily semaglutide against placebo in early symptomatic Alzheimers Disease (AD)
There were no statistically significant differences in post-hoc testing
contraindication screening and interaction checks are integral to study design
I like being recognized as such
Retatrutide/Cagrilitide 10 mg + 5 mg 199.99 Availability: 390 in stock Third Party Tested 14-Day Money Back Guarantee Fast Delivery Worldwide Laboratory test for this product View the certificate of analysis and laboratory verification for this product
